Lonapegsomatropin
- US DailyMed: Lonapegsomatropin
administration
- H01AC09 (WHO)
- 1934255-39-6
- 381128171
- DB16220
- OP35X9610Y
- D11486
- ChEMBL4298185
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1][3] Lonapegsomatropin is a prodrug of somatropin.[1]
Lonapegsomatropin was approved for medical use in the United States in August 2021,[1][2][5] and in the European Union in January 2022.[3]
Medical uses
Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][3]
History
The US Food and Drug Administration granted the application for lonapegsomatropin orphan drug designation.[6]
References
- ^ a b c d e "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Retrieved 30 September 2021.
- ^ a b "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 August 2021.
- ^ a b c d "Skytrofa EPAR". European Medicines Agency. 10 November 2021. Retrieved 16 March 2022.
- ^ "Skytrofa Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of Skytrofa (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency". Ascendis Pharma (Press release). 25 August 2021. Retrieved 25 August 2021.
- ^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023.
This article incorporates text from this source, which is in the public domain.
Further reading
- Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, et al. (July 2021). "Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial". The Journal of Clinical Endocrinology and Metabolism. 106 (11): 3184–3195. doi:10.1210/clinem/dgab529. PMC 8530727. PMID 34272849.
External links
- Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov
- v
- t
- e
glands
| Hypothalamic– pituitary |
| ||||||
|---|---|---|---|---|---|---|---|
| Adrenal axis | |||||||
| Thyroid | |||||||
| Parathyroid | |||||||
| Gonadal axis |
| ||||||
| Pancreas | |||||||
| Pineal gland |
| Thymus | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Digestive system |
| ||||||||
| Adipose tissue | |||||||||
| Skeleton | |||||||||
| Kidney | |||||||||
| Heart |
Portal:
Medicine
 | This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
